ArticleFrontiers in neurology2022
Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas.
Article in Frontiers in neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Diagnostic yield, safety, and molecular-era clinical utility of stereotactic biopsy for brainstem lesions: a contemporary systematic review and meta-analysis.Frontiers in surgery · 2026Pooled it
- A systematic review evaluating the effectiveness of nuclear medicine techniques in enhancing the diagnostic accuracy of stereotactic brain biopsies.Neurosurgical review · 2025Pooled it
- Visualising spatial heterogeneity in glioblastoma using imaging habitats.Frontiers in oncology · 2022Pooled it
- Outcomes of Laser Interstitial Thermal Therapy-Augmented Surgery in the Management of Subcortical Glioblastoma.Neurosurgery practice · 2026Article
- Association of recurrence patterns and outcome with HR and HER2 status in patients with resected brain metastases from breast cancer.International journal of cancer · 2026Article
- Fluorescence-aided stereotactic needle biopsies for brain tumors: experience on 516 cases.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Article
- Radiomics in glioblastoma recurrence: advances in prediction, localization, and differentiation from treatment-related effects.Journal of translational medicine · 2026Review
- Detection of IDH1.R132H mutant protein in plasma extracellular vesicles and its application in preoperative noninvasive precision diagnosis of glioma.BMC cancer · 2026Article
- Diagnostic yield and safety of frame-based versus robot-assisted stereotactic brain biopsy: a matched cohort analysis.Neurosurgical review · 2026Article
- Laser interstitial thermal therapy for IDH wild-type recurrent glioblastoma: a Scandinavian two-center cohort study.Acta neurochirurgica · 2026Article
- Diagnostic performance and safety of stereotactic frame-based biopsy for sub centimeter intracranial lesions: A matched cohort analysis.Neurosurgical review · 2026Article
- Decoding CNS granulomas: cracking the imaging mystery in tuberculosis and neurocysticercosis endemic zones.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026Observational
- Detection of Human Brain Cancers using Genomic and Immune Cell Characterization of Cerebrospinal Fluid through CSF-BAM.Cancer discovery · 2025Article
- The Silent Transformation of Stereotactic Brain Biopsies After the Introduction of Robotics.The international journal of medical robotics + computer assisted surgery : MRCAS · 2025Article
- A hitchhiker's guide to cerebrospinal fluid biomarkers for neuro-oncology.Neuro-oncology · 2025Review
- Stereotactically Guided Microsurgical Approach for Deep-Seated Eloquently Located Lesions.Journal of clinical medicine · 2025Article
- Liquid Biopsy-Derived Tumor Biomarkers for Clinical Applications in Glioblastoma.Biomolecules · 2025Review
- Investigative needle core biopsies support multimodal deep-data generation in glioblastoma.Nature communications · 2025Article
- Determinants of long-term survival in patients with IDH-mutant gliomas.Journal of neuro-oncology · 2024Article
- Patterns of intersectional tumor volumes in T2-weighted MRI and [Scientific reports · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: An integrated diagnosis consisting of histology and molecular markers is the basis of the current WHO classification system of gliomas. In patients with suspected newly diagnosed or recurrent glioma, stereotactic biopsy is an alternative in cases in which microsurgical resection is deemed to not be safely feasible or indicated. In this retrospective study, we aimed to analyze both the diagnostic yield and the safety of a standardized biopsy technique. Material and Methods: The institutional database was screened for frame-based biopsy procedures (January 2016 until March 2021). Only patients with a suspected diagnosis of glioma based on imaging were included. All tumors were classified according to the current WHO grading system. The clinical parameters, procedural complications, histology, and molecular signature of the tissues obtained were assessed. Results: Between January 2016 and March 2021, 1,214 patients underwent a stereotactic biopsy: 617 (50.8%) for a newly diagnosed lesion and 597 (49.2%) for a suspected recurrence. The median age was 56.9 years (range 5 months-94.4 years). Magnetic resonance imaging (MRI)-guidance was used in 99.3% of cases and additional positron emission tomography (PET)-guidance in 34.3% of cases. In total, stereotactic serial biopsy provided an integrated diagnosis in 96.3% of all procedures. The most frequent diagnoses were isocitrate dehydrogenase (IDH) wildtype glioblastoma ( Conclusion: Image-guided stereotactic serial biopsy enables obtaining reliable histopathological and molecular diagnoses with a very low complication rate even in tumors with critical localization. Thus, in patients not undergoing microsurgical resection, this is a valuable tool for precision medicine of patients with glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.